Skip to main content

Table 1 Patient characteristics

From: Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy

Patient ID

Age (years)

Serum PSA

(ng/ml)

Gleason score

Tumor stage (TNM)

P1

67

53.7

9

T3bN1M0

P2

56

183.8

9

T3bN1M1

P3

63

27.3

8

T3bN1M0

P4

52

58

8

T3bN1M0

P5

74

896

9

T3bN1M1

P6

58

239.7

9

T3bN1M0

P7

81

69.1

8

T3bN1M1

P8

53

104

9

T3bN1M1

P9

66

38.8

8

T3bN1M0

P10

73

127.4

8

T3bN1M1

  1. PSA prostate specific antigen, TNM tumor-node-metastasis